BioTuesdays

Category - Markets

Kiora Logo
Markets

Maxim starts Kiora Pharma at buy; PT $2.50

Maxim Group initiated coverage of Kiora Pharmaceuticals (NASDAQ:KPRX) with a “buy” rating and price target of $2.50. The stock closed at 80 cents on Jan. 18. Kiora is developing ophthalmic medicines including, KIO-101...

January 19, 2022
INVO Bioscience
Markets

Maxim starts INVO Bioscience at buy; PT $7

Maxim Group launched coverage of INVO Biosciences (NASDAQ:INVO) with a “buy” rating and $7 price target. The stock closed at $3.69 on Jan. 18. INVO is a commercial-stage company with the world’s first and only...

January 19, 2022
Markets

Maxim ups Daré Biosciences PT to $4 from $3

Maxim Group raised its price target for Daré Bioscience (NASDAQ:DARE) to $4 from $3, citing FDA approval of XACIATO vaginal gel as a treatment for bacterial vaginosis (BV) and a commercial launch in 2022. The stock...

January 18, 2022
acutus logo
Markets

Canaccord cuts Acutus Medical to hold; PT to $3

Canaccord Genuity downgraded Acutus Medical (NASDAQ:AFIB) to “hold” from “buy” and slashed its price target to $3 from $10, citing a financing/dilution risk. The stock closed at $3.02 on Jan. 13. Acutus is an arrhythmia...

January 14, 2022
Markets

Maxim starts Genenta Science at buy; PT $21

Maxim Group launched coverage of Genenta Science S.p.A (NASDAQ:GNTA) with a “buy” rating and $21 price target. The stock closed at $9.94 on Jan. 12. Genenta is developing cancer therapeutics using an autologous ex...

January 13, 2022
Bionomics
Markets

Analysts start Bionomics at OW, OP

Analysts for Cantor Fitzgerald and William Blair launched coverage of Bionomics (NASDAQ:BNOX) with “overweight” and “outperform” ratings, respectively. Australia-based Bionomics is a clinical-stage biopharmaceutical...

January 10, 2022
NeuroSense Therapeutics
Markets

Maxim starts NeuroSense at buy; PT $7

Maxim Group initiated coverage of NeuroSense Therapeutics (NASDAQ:NRSN) with a “buy” rating and price target of $7. The stock closed at $2.53 on Jan. 6. NeuroSense is a clinical-stage company developing therapies for...

January 7, 2022
Markets

Maxim starts Quoin Pharma at buy; PT $5

Maxim Group initiated coverage of Quoin Pharmaceuticals (NASDAQ:QNRX) with a “buy” rating and price target of $5. The stock closed at $1.74 on Jan.6. Quoin is a clinical-stage company developing therapies for rare...

January 7, 2022